| Lam, David CL |
| Recruiting | 1/2 | 360 | Europe, US | MCLA-158, petosemtamab, MCLA-158 +Pembrolizumab | Merus N.V., Chiltern International Inc., Q2 Solutions, Oncology Therapeutic Development (OTD), 4Clinics | Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma | 06/24 | 06/25 | | |
| Active, not recruiting | 1/2 | 334 | Europe, Japan, US, RoW | TAK-788, AP32788 | Takeda | Carcinoma, Non-Small-Cell Lung | 03/25 | 03/25 | | |
|
|
NCT05198284: Prospective Decision Impact Clinical Utility Trial of KidneyIntelX |
|
|
| Active, not recruiting | N/A | 2000 | US | KidneyIntelX | Renalytix AI, Inc. | Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3 | 12/23 | 11/26 | | |
NCT05762731: Screening for Lung Cancer in Subjects With Family History of Lung Cancer |
|
|
| Recruiting | N/A | 1520 | RoW | Low dose CT thorax | The University of Hong Kong, The Queen Elizabeth Hospital, Kwong Wah Hospital, Hong Kong Sanatorium & Hospital | Lung Cancer | 12/24 | 12/25 | | |
| Levy, Carol |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Active, not recruiting | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 06/24 | 10/24 | | |
NCT04905628: Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus |
|
|
| Recruiting | N/A | 100 | US | Dexcom CGM System | DexCom, Inc. | Diabetes Mellitus | 03/22 | 04/22 | | |
NCT05403502: Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes |
|
|
| Completed | N/A | 183 | US | t:slim X2 insulin pump with Control-IQ technology 1.5 | Tandem Diabetes Care, Inc., Eli Lilly and Company, Jaeb Center for Health Research | Type 1 Diabetes | 08/23 | 08/23 | | |
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 335 | Canada, US | t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM) | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type 2 Diabetes Treated With Insulin | 09/24 | 09/24 | | |
CGM-DTx, NCT06111508: The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants. |
|
|
| Recruiting | N/A | 30 | US | Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs, Degludec | University of Virginia, Novo Nordisk A/S | Type 2 Diabetes | 08/24 | 08/24 | | |
| Mehran, Roxana |
NCT01456013: Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients |
|
|
| Active, not recruiting | 3 | 326 | US | RenalGuard Therapy, Standard Therapy | CardioRenal Systems, Inc. | Contrast Induced Nephropathy | 03/18 | 12/24 | | |
| Completed | N/A | 19000 | US | Percutaneous coronary intervention | Abbott Medical Devices, Icahn School of Medicine at Mount Sinai | Coronary Artery Disease, Percutaneous Coronary Intervention | 02/21 | 10/23 | | |
ABILITY, NCT04236609: Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global |
|
|
| Active, not recruiting | N/A | 3050 | Europe, RoW | Abluminus DES+ Sirolimus Eluting Stent System (SES), XIENCE Everolimus Eluting Coronary Stent System (XIENCE family) | Concept Medical Inc. | Diabetes, Coronary Artery Disease, Acute Coronary Syndrome | 10/23 | 09/24 | | |
| Recruiting | N/A | 418 | Europe, US, RoW | SELUTION SLR™ DEB, Control | M.A. Med Alliance S.A., Iqvia Pty Ltd | Coronary Restenosis | 07/24 | 11/27 | | |
| Active, not recruiting | N/A | 716 | Europe, Canada, US, RoW | Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems, Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems | Medtronic Cardiovascular | Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement | 11/23 | 12/27 | | |
| Completed | N/A | 322 | US | Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) | Element Science, Inc. | Sudden Cardiac Arrest | 11/23 | 11/23 | | |
| Recruiting | N/A | 500 | US | ProtEmbo - Cerebral Embolic Protection, Sentinel - Cerebral Embolic Protection | Protembis GmbH | Severe Aortic Valve Stenosis | 06/25 | 07/25 | | |
| Seidler, Christine |
| No trials found |
